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Abstract
Background: IgA nephropathy (IgAN) is the most common form of glomerulonephritis, a principal cause of end-stage
renal disease (ESRD) worldwide. The mechanisms of onset and progression of IgAN have not been fully revealed, and
epidemiologic studies have yielded diverging opinions as to the role of occupational exposure to organic solvents in
the initiation or worsening of IgAN. As the authors encountered a laboratory worker with IgAN that progressed to
ESRD, we present a case report of IgAN progression due to dichloromethane exposure along with a review of literature.
Case presentation: A 41-year-old male laboratory worker began to experience gross painless hematuria after two
years of occupational exposure to toluene. Although clinical follow-up was initiated under the impression of IgAN
based on clinical findings, the patient continued to work for four more years in the same laboratory, during which he
was in charge of laboratory analysis with direct exposure to a high concentration of dichloromethane without proper
protective equipment. During that time, his renal function rapidly worsened and finally progressed to ESRD 10 years
after the first clinical symptoms. The result of exposure assessment through reenactment of his work exceeded the
occupational exposure limit for dichloromethane to a considerable degree.
Conclusions: The causal association between occupational solvent exposure and IgAN is still unclear; therefore, this
case report could be used as a basis to support the relevance of occupational solvent exposure to IgAN and/or its
progression. Early intervention as well as close monitoring of laboratory workers exposed to various organic solvents is
important to prevent or delay the progression of glomerulonephritis to ESRD in the occupational setting.
Keywords: IgA nephropathy, End-stage renal disease, Organic solvent, Occupational exposure, Laboratory worker,
Toluene, Dichloromethane
Background
IgA nephropathy (IgAN) is a glomerular disease charac-
terized by IgA deposition in the glomerular mesangium
of the kidney, which was first reported by Berger et al. in
1968 [1]. IgAN is the most common form of glomerulo-
nephritis in the world, accounting for about 30–45 % of
all primary glomerular diseases [2]. IgAN can occur in
all age groups, but is mainly found in patients in their
10s–30s, and it is more common in males, with a male
to female gender ratio of 2:1 [3, 4]. The disease can be
diagnosed through biopsy by visualization of IgA
deposition in the glomerular mesangial area using im-
munofluorescence microscopy [2, 4]. IgAN presents with
macroscopic hematuria in about 40 to 45 % of patients,
with microscopic hematuria and proteinuria in about 35
to 40 %, and with nephrotic syndrome or acute renal
failure in the remainder [3, 5]. While IgAN has an indo-
lent course, about 30 % of patients will reach end-stage
renal disease (ESRD) after 20 years, particularly in those
who present with hypertension, heavy proteinuria or
renal insufficiency [3–5]. Still no treatment is known to
modify mesangial deposition of IgA, and available treat-
ment options are directed to mostly at downstream im-
mune and inflammatory events that may lead on to
renal scarring [4]. Although the etiology and pathophysi-
ology of IgAN have not yet been clearly identified,
accumulating evidence suggests that the onset and
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progression are caused by interactions between various
genetic and environmental factors [6–9]. Among them,
occupational risk factors such as exposure to organic
solvents have been suggested as probable causes that
may induce [7, 8, 10] or aggravate IgAN [11–13].
The present case report is the first report in Korea
suggesting the possibility that occupational exposure to
organic solvents such as toluene and dichloromethane,
commonly used in laboratories and industrial fields, can
act as a risk factor for the onset and/or progression of
IgAN. The present case report attempted to investigate
the association of occupational solvent exposure and
IgAN based on patient clinical information, inspection
of the working environment, exposure assessment, and
review of related literature, by which the authors aimed
to contribute to the approach and prevention of other




Male, 55 years old (at the time of clinic visit for the
assessment of occupational disease).
Chief complaint
End-stage renal disease with histories of gross painless
hematuria and chronic fatigue.
Present illness
He first experienced the symptom of gross painless
hematuria in June 2000, when he was 41 years old. Urin-
alysis performed in A hospital in December 2000 identi-
fied hematuria and proteinuria, while the serum creatinine
(Cr) concentration was in the normal range (red blood
cells [RBC]: Many, Cr: 1.3 mg/dL, 24 h urine protein:
266.2 mg/day). The patient was hired in the current la-
boratory institute in 1987, when he was 28 years old. Be-
fore the first episode of gross hematuria, for 2 years and
7 months (February 1998 to August 2000), corresponding
to ages 39 to 41 years for the patient, his work involved
analysis of the dioxin contents in exhaust gas at an incin-
eration facility by a pretreatment method using toluene in
the laboratory.
In July 2001, the patient was clinically diagnosed with
IgAN without a biopsy in B hospital, and clinical follow-up
was initiated. Although the patient was in follow-up after
the clinical diagnosis with IgAN, he performed work involv-
ing analysis of total petroleum hydrocarbon (TPH) in soil
samples using a dichloromethane as a solvent again in the
laboratory for 4 years and 4 months (March 2005 to June
2009), corresponding to ages 46 to 50 years. During the
TPH analysis work, the patient was continuously exposed
to dichloromethane in a laboratory under conditions of
poor ventilation without appropriate protective devices
such as a respirator and gloves. The Cr level in the patient’s
blood test started to increase from April 2006 (April 2006,
Cr: 1.7 mg/dL; November 2007, Cr: 2.2 mg/dL), followed
by exacerbation of the systemic fatigue symptom, so he was
admitted to C hospital in March 2008, when he was 49 years
old, and diagnosed with IgAN by a biopsy. Since 2008, the
patient’s renal function rapidly deteriorated (June 2009, Cr
3.9 mg/dL; September 2009, Cr 5.9 mg/dL; April 2010, Cr
8.4 mg/dL) and finally progressed to ESRD, and peritoneal
dialysis was begun in June 2010 when he was 51 years old.
As of December 2014, he was in follow-up after kidney
transplantation at the age of 55 years, after 13 years had
passed from the initial clinical diagnosis with IgAN.
Clinical therapeutic course
The patient began to take an angiotensin II receptor
blocker (ARB) after clinical diagnosis in 2001, and
thereafter, the patient’s blood pressure, serum BUN/Cr
level, and urine protein/creatinine ratio (PCR) have
been measured at regular outpatient follow-ups. He
incorporated life style modifications for weight man-
agement and abstained from alcohol, and started a
low-salt, low-protein diet with the initiation of medi-
cation. When his serum Cr increased to 1.7 mg/dL in
April 2006, he began taking an angiotensin-converting
enzyme inhibitor (ACEi), HMG-CoA reductase inhibi-
tor (statin), omega-3, and blood pressure medication,
and his blood pressure, renal function, and proteinuria
level were closely monitored. However, the patient’s
renal function and proteinuria level began to deterior-
ate in 2008, and he ceased analytic work in the lab
and changed to a desk job in June 2009. Despite start-
ing oral steroid therapy in September 2009, no par-
ticular benefit was observed, and the patient began
peritoneal dialysis in June 2010, eventually undergoing
renal transplantation in December 2014.
Past history
The patient had a history of diagnosis at the age of
21 with pleural effusion and tuberculous pleurisy,
which was completely cured after a two-year course of
medication. Other than that, his past medical history
is essentially unremarkable. There is no evidence of
preexisting hypertension, cardiovascular disease, dia-
betes mellitus, and there is no preexisting history of
drug abuse, alcoholism or medication abuse. The pa-
tient received regular occupational health examinations
two times (in 1997 and 1999) before the onset of his
first symptom of hematuria and had no abnormal
findings on the corresponding health examinations, in
particular, on kidney-related examinations such as
hematuria and proteinuria.
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Family history
His family history is essentially unremarkable. When the
family history of the patient was thoroughly examined, no
first-degree relatives had any history of specific disease in-
cluding kidney disease.
Social history
The patient was not smoking and his alcohol intake his-
tory was 3–4 times a month, with about 0.5 bottle of soju
each time.
Pathologic examination
Eight years after the first clinical symptom appeared, the
patient was finally confirmed to have IgAN (subclass V, by
Haas histological classification [14]) through a kidney
biopsy, in March 2008 when he was 49 years of age. The bi-
opsy findings were as follows: “Tubules reveal focal moder-
ate atrophy or loss with focal moderate infiltration of
mononuclear cells and fibrosis in interstitium. Fibrointimal
thickening of small arteries is noted.”
Lab test follow-up
The authors reviewed all the medical records of the
patient, focusing on the assessment of all serum Cr
test results on every medical record from February
1997, when the patient first underwent health exam-
ination since the beginning of the job. As a result, we
found that his serum Cr level rapidly increased from
the period when he was exposed to dichloromethane




The first job of the patient was environmental design-
related office work in H company, where he worked for
3 years from 1984, when he was 25 years of age, and he
transferred to the current job in May 1987, when he was
28 years of age. Except for the period when the patient
performed general office work, he was continuously in-
volved in sample analysis work in a laboratory, in which
periods and tasks in which he was exposed to organic
solvents are as follows: 1) Dioxin analysis using toluene
pretreatment in the laboratory for 2 years and 7 months
(February 1998 to August 2000), since 39 years of age;
and 2) TPH analysis of soil by pretreatment using di-
chloromethane for 4 years and 4 months (March 2005
to June 2009), since the age 46 (Table 1).
Among these tasks, according to our preliminary study,
TPH analysis work using dichloromethane was suspected
as the work in which the patient was exposed to organic
solvents in a high concentration for a long period of time
without proper protective devices; considering whether
the presence of relevant data and the possibility of recon-
struction of working environment, the present case report
was focused on the TPH analysis work in detail for evalu-
ation of occupational exposure, during which the patient’s
IgAN rapidly progressed to ESRD.
Job analysis
The pretreatment work in TPH analysis of soil that the
patient performed was conducted according to the
ultrasound-assisted extraction method of TPH in item
number 18 of the Standard Test Method of Soil Con-
tamination by the Ministry of Environment of Korea,
and its schematic process is presented in Fig. 2. The
Fig. 1 Changes in creatinine (Cr) levels according to period of exposure to organic solvents and lapse of time; Dots on the line indicate time
points when Cr levels were measured. The first and second measurements of Cr levels were made in February 1997 and May 1999, when the
patient was 38 and 40 years old, respectively. Cr levels were measured every 6–12 months after 1999, every 2 months starting in 2007 (when the
patient was 48 years old), and every month starting in 2008 (when the patient was 49 years old)
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patient reported 4–8 h of daily exposure and described
symptoms of dizziness, headaches, and nausea during
the pretreatment process. Despite consideration of the
general office tasks he did in parallel with TPH analysis
work, when the working hours of TPH analysis were es-
timated based on the descriptions of the patient and co-
workers during the 4 years and 4 months, the exposure
frequency to dichloromethane of the patient was at least
4 h/day, so the exposure frequency was speculated to be
quite high.
Exposure environments
The authors investigated the work environment of the
laboratory institute and reviewed all past work environ-
ment data measurements. Pretreatment process in TPH
analysis was performed in ‘Room A’ before 2008, where
the door always remained closed during experiments
due to the noise generated in the pretreatment process.
According to the descriptions by the patient and co-
workers, a local ventilation system had been installed for
ventilation, but ventilation conditions were poor and
workers often performed pretreatment works without
the provision of protective devices such as a respirator
and gloves. The location for pretreatment work of TPH
analysis was changed in 2008 to ‘Room B’ (123.8 m2)
with an area about 4 times larger than ‘Room A’
(30.1 m2). In addition to a preexisting ventilation system
in ‘Room B’, an additional local ventilation system was
installed in 2010, and three ultrasound-assisted extrac-
tors (the major source of dichloromethane) were placed
in the newly installed hood facilities.
According to the results of working environment meas-
urement in 2011, however, levels of dichloromethane ex-
posure in two laboratory workers who performed the
corresponding pretreatment work using dichloromethane
in ‘Room B’ were 90.239 ppm and 53.045 ppm, exceeding
50 ppm, the time-weighted average (TWA) suggested in
Korean Industrial Safety and Health Act (Table 2).
Exposure assessment through reenactment
The work space of ‘Room A’, where the work was
actually carried out at that time, was accurately restored
and the process of ultrasound-assisted extraction using
dichloromethane was reenacted repeatedly for about 2 h
following the same method that the patient had actually
performed (Fig. 3). Predictable errors were minimized by
referring to coworkers who performed the work with
Table 1 The patient’s history of occupational exposure to organic solvents with disease progression
Duration Task Possible exposure Disease history
Feb 1998 to Aug 2000 Dioxin analysis Toluene Jun 2000: Hematuria onset
Jul 2001: Clinical diagnosis of IgAN
Jul 2001: Clinical follow-up starts
Mar 2005 to Jun 2009 TPH analysis Dichloromethane Oct 2006: Renal function exacerbation
Mar 2008: Renal biopsy confirmed
Jun 2010: Peritoneal dialysis starts
Dec 2014: Kidney transplantation
Fig. 2 The Standard Test Method of Soil Contamination on TPH
pretreatment by the Ministry of Environment of Korea (Ultrasound-
Assisted Extraction method)
Table 2 Exposure assessment history of the corresponding
workplace for pretreatment work
Year Measurement result (ppm)
Dichloromethane Mixed organic
compounds




OELa (TWAb) 50 1
aOEL: Occupational Exposure Limit
bTWA: Time-Weighted Average
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patient and managers. For measurement, samples in the air
during the work of ultrasound-assisted extraction were col-
lected. Detailed measurement and analysis of dichloro-
methane in the air was performed based on the 1005
method of the US National Institute of Occupational Safety
& Health (NIOSH). As a result of the measurement, the
time-weighted average concentrations of dichloromethane
at the corresponding spots where pretreatment workers
were positioned were 254 and 181 ppm, respectively, and
the ranges of short-term exposure concentration were 68–
374 ppm and 88–359 ppm, respectively (Table 3).
These results suggest that the actual respiratory expos-
ure concentrations of the patient to dichloromethane in
‘Room A’ during the pretreatment work for TPH analysis
during the period of March 2005 to June 2009 should have
been higher than the time-weighted average (50 ppm) set
by the Korean Industrial Safety and Health Act and the
short-term exposure limit (125 ppm) set by OSHA (Occu-
pational Safety and Health Administration). Therefore, it
can be surmised that the patient had been regularly ex-
posed to a high concentration of dichloromethane in
‘Room A’ for 52 months.
Discussion
A number of studies have reported kidney toxicity of or-
ganic solvents and an association with glomerulonephritis.
Miller et al. [15] reported a case of acute tubular necrosis
accompanied by acute renal failure, myoglobinuria, and
liver enzyme elevations that were caused by inhalation ex-
posure to dichloromethane. They conclude that dichloro-
methane may have potential as both a hepatotoxic and
nephrotoxic agent when inhaled at high concentrations
over an extended period of time [15]. Ana-Lilia et al. [16]
reported that shoe-workers who were occupationally ex-
posed to toluene-based glues had a higher risk of renal
glomerular and/or tubular damage than the control group.
Ravnskov et al. [17] conducted a meta-analysis of 14 case–
control studies and reported that the combined data sup-
port the hypothesis that hydrocarbon exposure increases
the risk of chronic renal disease, although no specific hy-
drocarbons were identified in these reviews. In addition,
there have also been other case reports [18], epidemio-
logical studies [8, 19, 20] and animal-experimental studies
[19, 21] reporting associations between solvent exposure
and onset of glomerulonephritis or deterioration of renal
function. On the other hand, a few studies [22, 23] re-
ported negative results on the association between solvent
exposure and the risk of chronic glomerulonephritis.
In the clinical literature that specifically reported IgAN
in relation to occupational exposure, several case studies
reported the onset of IgAN due to exposure to organic
solvents [24, 25], in addition to cadmium [24, 26, 27] and
silica [28] (Table 4). Albrecht et al. [25] reported the case
of a 28-year-old male pipe plumbing worker who devel-
oped IgAN after occupational exposure to organic solvents.
The corresponding patient was exposed to organic solvents
Fig. 3 Site of exposure reenactment (Two ultrasound-assisted extractors
are located inside separate hood chamber). Measurement position a. In
front of Extractor 1. Measurement position b. In front of Extractor 2.
Measurement position c. Above the two Extractors



























C. Above the ultrasound-
assisted extractors
113 - 179
OEL (Occupational exposure limit): Time-weighted average 50 ppm (the Korean
Industrial Safety and Health Act), short-term exposure limit 125 ppm (OSHA)
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during 9 years and 6 months of pipe plumbing work,
resulting in the symptom of gross hematuria, and he was
diagnosed with IgAN by a biopsy [25]. Working environ-
ment measurement identified that the patient mainly car-
ried out pipe plumbing tasks in closed bathrooms, during
which he was exposed to a high concentrations (389–
757 ppm) of tetrahydrofuran (THF), a component of poly-
vinyl chloride (PVC) pipe cement (the short-term exposure
limit for THF set by the NIOSH is 250 ppm) [25]. The au-
thors stated that a predisposition toward IgAN in this pa-
tient could be exacerbated by massive short-term exposure
to the solvent [25].
Meanwhile, Fernandez et al. [24] introduced a case of
IgAN in a 50-year-old male who was exposed to various
types of organic solvents for 23 years. The male was
continuously exposed to organic solvents occupationally
for an additional two years even after diagnosis with
IgAN, resulting in progression to CRF stage 3 in two
years after diagnosis with IgAN [24].
Literature searches on epidemiologic studies that ana-
lyzed correlations between IgAN and occupational solvent
exposure resulted in a total of three case–control studies
reported to date [10, 11, 29] (Table 5). First, Porro et al.
[10] investigated occupational and non-occupational
exposures to organic solvents in 60 chronic glomerulo-
nephritis patients diagnosed by biopsy in the Bari area of
Southern Italy and a control group (60 nephrolithiasis and
60 traumatic fracture patients) from 1983 to 1987. The
odds ratio of chronic glomerulonephritis for patients
occupationally exposed to solvents was 3.9 (95 % confi-
dence interval [CI] 1.64–8.33), and a logistic regression
model showed a dose–response relationship of occupa-
tional exposures to solvents and glomerulonephritis [10].
When IgAN patients (n = 27) were separately evaluated,
an increased risk was found for both total (Relative risk
[RR] = 3.5, 95 % CI 1.18–12.18) and occupational exposure
(RR = 4.25, 95 % CI 1.18–16.36) [10].
In contrast, a case–control study that was conducted
by Wakai et al. [29] with Japanese subjects to investigate
a correlation between diagnosis of IgAN and occupa-
tional exposure to organic solvents showed an odds ratio
of 0.55 (95 % CI 0.27–1.12), which was not statistically
significant [29]. The authors commented that they might
have failed to find a positive association because of the
few number of patients with advanced renal failure, and
also pointed out that another possible limitation was the
methodological difficulty of measuring exposure to or-
ganic solvent [29].
Meanwhile, Stengel et al. [11] performed a case–con-
trol study to investigate a correlation between organic
solvent exposure and CRF with 116 IgAN patients in five
hospitals in Paris. As a result, among males, a clear asso-
ciation was observed between CRF and high exposure to
organic solvents for IgAN patients (OR = 3.5, 95 % CI
1.0–11.8) [11]. In addition, the odds ratio increased with
duration of exposure [11]. On the other hand, patients
with IgAN who had normal renal function showed no
correlation with organic solvents, so these results were
interpreted to suggest that organic solvents contributed
to deterioration of renal function to some degree rather
than to the diagnosis itself of IgAN [11].
Meanwhile, in 2007, Jacob et al. [12] conducted the
GN-PROGRESS cohort study; the authors investigated
occupational risk factors for the progression of glom-
erulonephritis to ESRD. Using a cohort study design,
they showed that solvent exposure was indeed associ-
ated with faster progression to ESRD with IgAN
(Hazard ratio [HR] = 2.6, 95 % CI 1.3–5.5) [12]. In pa-
tients with IgAN, there was a trend in increased haz-
ard ratios with exposure duration before and its
persistence after diagnosis [12].
In a subsequent study, using data from the GN-
PROGRESS cohort, Jacob et al. [13] therefore systemat-
ically investigated the risk of progression to ESRD, by
solvent-exposed job category, type of solvent-containing
products, and by solvent or solvent family. In this ana-
lysis [13], they focused on the 269 patients with either
IgAN or membranous nephropathy. Among solvents,
the highest risks were found for: toluene/xylene (HR =
5.1, 95 CI 1.8–14.8), gasoline, fuel and gas-oil (HR = 8.6,
95 CI 2.7–27.4), and ketones (HR = 13.3, 95 % CI 1.4–
123.5). Most interestingly, they also observed an excess
risk for any exposure level to methylene chloride, also
known as dichloromethane (HR = 6.4, 95 % CI 1.7–24.8)
[13]. In another occupational cohort study in US aircraft
workers, Radican et al. [30] pointed to the risk of all-
cause ESRD associated with trichloroethylene, 1,1,1-tri-
chlorethane, dichloromethane, and JP4 gasoline.
Table 4 Case reports of IgAN associated with occupational solvents exposure
Author(s) (year) Gender/Age at
diagnosis





Male/28y A plumber, working
with solvent-based
pipe cement










23 years + progression to
CRF in 2 years
after diagnosis
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In summary, regarding the relationship between occupa-
tional solvent exposure and IgAN in the literature, all
reviewed studies [11, 12] consistently reported significant
correlations at least between solvent exposure and the pro-
gression of preexisting IgAN to CRF or to ESRD, though
study results regarding the onset of IgAN [10, 11, 29] were
inconsistent (Table 5). In particular, recent cohort study re-
sults [12, 13, 30], showing the potential role of toluene and
dichloromethane in the progression of IgAN to ESRD sup-
ports our hypothesis that the IgAN of this case report may
have progressed more rapidly to ESRD due to occupational
solvent exposure.
Although it can occur at any age, IgAN mainly occurs in
young adults (16–35 years old) [3, 31–33]. In a Chinese
cohort study of 1,115 patients with IgAN [34], the mean
age at time of initial clinical manifestations and renal bi-
opsy were 31 ± 9, and 33 ± 9 years old, respectively. For
the patient in the present case, gross hematuria was first
experienced at 41 years of age in June 2000, and the serum
Cr level at that time was 1.3 mg/dL, corresponding to a
normal level. In July 2001, he was given a clinical diagno-
sis of IgAN (not biopsy confirmed), which was when the
patient was 42 years old. This is much older than the usual
age for initial clinical presentation and diagnosis of IgAN
compared to the mean age of diagnosis (10–30 years) re-
ported in other studies [31, 32, 34], so it was suspected
that this case could be different from the general cases
that were diagnosed at earlier ages, at about 10–30 years,
mostly due to internal or genetic factors.
For the natural history of IgAN, the actuarial renal
survival rate for 10 years after diagnosis or after a biopsy
is a significant parameter for prognosis prediction of
IgAN [31, 35]. According to a meta-analysis by Coppo
[35], the actuarial renal survival rate for 10 years after
diagnosis with IgAN or after a biopsy was mostly about
80–90 % in Europe, Asia and Australia. Another study
conducted in United Kingdom, using Medical Research
Council’s Glomerulonephritis Registry [36], reported that
the 10-year cumulative renal survival rate was 83.3 %. Le
et al. [34] reported a cohort study with 1,115 IgAN pa-
tients in China, in which renal survival rates after diag-
nosis with IgAN were 83 at 10 years, 74 at 20 years, and
64 % at 30 years. In contrast to the actuarial renal sur-
vival rate of 80–90 % for 10 years reported in the litera-
ture [31, 34–36], this patient experienced rapid
deterioration of renal function within only 9 years from
the initial clinical diagnosis to dialysis. Thus, the progno-
sis is extraordinarily poor.
Table 5 Epidemiological studies investigating the association of occupational solvent exposure and IgAN
Author(s)
(year)








GNa patients in a University
hospital in Italy (including
27 IgAN patients)
onset of IgAN 1987–1990 60/27
(reference:120)
·An increased risk of IgAN was found
for occupational solvent exposure
group.
·RRb of IgAN for occupational solvent





298 biopsy-proven GNa pa-







·Among males, clear association was
observed between CRF and high
exposure to solvents for IgAN; ORc =
3.5 (1.0–11.8), P < 0.05.
·The OR increased with duration of
exposure; OR = 5.6 (1.3–24.1) for
≥10 years exposure, (P = 0.02).






94 biopsy-proven IgAN pa-
tients in medical centers in
Japan
onset of IgAN 1997–1999 94/94
(reference:185)
· Work-related exposure to organic
solvents was found not to be associ-
ated with the risk for IgAN; OR = 0.55





338 non-ESRD patients in





2002–2004 338/194 ·Solvent exposure was associated
with faster progression of IgAN to
ESRD, HRd for IgAN is 2.6 (1.3–5.5) for
high exposure versus none (p < 0.05).
·There was a trend increasing HR
with exposure duration before and





269 patients with non-
ESRD and biopsy-proven
primary GNa diagnosis be-
tween 1994 and 2001 in
Paris and suburbs (includ-
ing 167 IgAN patients)
aggravation of
IgAN to ESRD
2002–2004 269/167 ·This study showed the potential role
of toluene and xylene, some
petroleum products, ketones and
possibly dichloromethane in the
progression of GNa to ESRD.
aGN, Glomerulonephritis; bRR, Relative Risk; cOR, Odds Ratio; dHR, Hazard Ratio; e(··), 95 % Confidence Interval
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On the other hand, studies on factors enabling predic-
tion of the prognosis of IgAN commonly suggested “un-
favorable histopathologic findings” such as glomerular
sclerosis and interstitial fibrosis, and “severe proteinuria at
presentation,” “arterial hypertension at presentation and
during follow-up,” and “elevated serum creatinine at pres-
entation” as strong clinical predictors [31, 37–39]. The pa-
tient in this case did not have confirmation by biopsy until
8 years after the first onset of symptoms. Since biopsy was
performed when histological damages had already pro-
gressed significantly, it is difficult to predict the prognosis
based on the time points of first onset and first diagnosis
based on biopsy findings. Meanwhile, this patient had a
serum Cr level of 1.3 mg/dL at the time of initial clinical
diagnosis, corresponding to within the normal range, and
266 mg/day of 24 h urine protein, showing that he was
not in a severe condition. Furthermore, the patient had
neither underlying diseases such as hypertension and dia-
betes from the past, nor hypertension at the time of diag-
nosis. In other words, although the patient was in a
condition without known strong clinical predictors, the
deterioration of his renal function rapidly progressed,
unlike the natural progression reported in other studies
[31, 34, 36]. In addition, this decline of renal function
overlapped with the patient’s period of exposure to dichlo-
romethane between March 2005 and June 2009 (Fig. 1).
In summary, based on a literature review of the nat-
ural history of IgAN, the present case has unusual clin-
ical characteristics such as the age of disease onset,
speed of progression, and the prognostic pattern. The
authors surmised that the unusual characteristics of this
IgAN case provide supporting evidence for the relevance
of occupational solvent exposure with IgAN and/or its
progression.
This case study has several limitations. First, exposure as-
sessment for toluene could not be conducted because there
were almost no relevant data remains. The first episode of
hematuria, the initial clinical manifestation of IgAN in this
patient, actually began after he had been exposed to toluene
while performing analysis of dioxin contents in exhaust gas
from an incineration facility during a period of 2 years and
7 months (Table 1). According to reports by the patient
and co-workers, however, there was no proper ventilator
system in the pretreatment room at that time, and workers
usually did not wear protective equipment. Thus, it is pre-
sumed that there was direct exposure to a high concentra-
tion of toluene. Therefore, the authors cautiously suggest
that possibilities of a causal relationship between toluene
exposure and the onset and/or aggravation of IgAN could
not be ruled out in present case. Secondly, despite the
attempt to minimize errors by restoration of the past actual
working environment at the site of investigation for expos-
ure, there may still be errors in perfect reflection of the past
working environment for the patient including ventilation
conditions and the circulation of worker’s traffic. Thirdly,
the health effects of other chemical substances used in the
laboratory where the patient worked, or potential secondary
health effects generated while various chemicals were used
in combination with organic solvents, were not evaluated.
In addition, another drawback in this case report is that
biological monitoring markers for dichloromethane such as
blood levels of carboxyhemoglobin (COHb) or urinary di-
chloromethane [40, 41] were not evaluated in the exposure
assessment.
Conclusion
This case report suggests that many laboratory workers
may be exposed to high levels of various hazardous chemi-
cals including organic solvents. Although the results are
controversial, several previous studies have suggested an as-
sociation between occupational solvent exposure and the
onset of IgAN and/or its progression to ESRD; thus, the
IgAN and following ESRD in this patient might have been
influenced by prolonged, high exposure to organic solvents.
Because IgAN is a major cause of ESRD and there is no
disease-targeted treatment, close monitoring to encourage
screening for proteinuria, hematuria, or hypertension in
workers exposed to organic solvents is crucial for early
detection of those with a risk for IgAN. Furthermore, early
intervention and elimination of exposure in those diag-
nosed with glomerulonephritis at an early stage may pre-
vent or delay the progression to ESRD in these workers.
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